Peter Levins, MD
Family Medicine · Phoenix, AZNPI 1407876303
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,570 of the $2,306 with a category attached, or 68.1%. 21 manufacturers reported payments, led by Novo Nordisk AS at 43.6% of the total. Reporting peaked in 2019 at $1,910 and has fallen 94.0% since, to $115 in 2023.
Across 84 payments — averaging $27.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$1K
- AstraZeneca$259
- AbbVie$150
- Amgen$112
- Pfizer$108
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$96
- plus $575 from 15 others
Across 807 payments — averaging $1200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$463K
- Kowa Research Institute, Inc.$255K
- Sanofi Pasteur Inc.$94K
- GSK$65K
- Akcea Therapeutics, Inc.$37K
- Sanofi US Services Inc.$31K
- plus $22K from 2 others
What the payments were for
- Travel & lodging$73632%
- Food & beverage$1,57068%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 5 | $1,006 |
| AstraZeneca | 15 | $259 |
| AbbVie(2 entities) | 8 | $150 |
| Amgen | 5 | $112 |
| Pfizer | 6 | $108 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $96 |
| Novo Nordisk | 7 | $94 |
| GSK | 5 | $87 |
| Sanofi Pasteur Inc. | 4 | $63 |
| Astellas Pharma US Inc | 3 | $54 |
| Lilly USA, LLC | 4 | $48 |
| Sanofi-aventis U.S. LLC | 3 | $41 |
| Boehringer Ingelheim | 2 | $32 |
| Genentech USA, Inc. | 2 | $30 |
| Johnson & Johnson | 2 | $30 |
| Novartis | 2 | $28 |
| Indivior Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Merck | 1 | $12 |
| Medtronic | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$957
How this compares
$2,306 in reported general payments places this provider in the 80th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 56 | $64,539 |
| MounjaroTirzepatide | 34 | $43,257 |
| EliquisApixaban | 33 | $40,464 |
| JardianceEmpagliflozin | 42 | $39,197 |
| TrulicityDulaglutide | 16 | $30,288 |
| FarxigaDapagliflozin Propanediol | 17 | $27,069 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $22,388 |
| MyrbetriqMirabegron | 19 | $17,945 |
| XareltoRivaroxaban | 11 | $13,201 |
| JanuviaSitagliptin Phosphate | 11 | $10,238 |
| TrintellixVortioxetine Hydrobromide | 15 | $3,620 |
| Rosuvastatin Calcium | 206 | $3,288 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $3,189 |
| SynthroidLevothyroxine Sodium | 41 | $3,166 |
| Levothyroxine Sodium | 296 | $2,475 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $48 | $73,54550 claims |
| Novo NordiskOzempic | $94 | $64,53956 claims |
| PfizerEliquis | $108 | $40,46433 claims |
| Boehringer IngelheimJardiance | $32 | $39,19742 claims |
| AstraZenecaFarxiga | $259 | $27,06917 claims |
| GSKTrelegy Ellipta | $87 | $22,38812 claims |
| Astellas Pharma US IncMyrbetriq | $54 | $17,94519 claims |
| Johnson & JohnsonXarelto | $30 | $13,20111 claims |
| MerckJanuvia | $12 | $10,23811 claims |
| AbbVieSynthroid | $150 | $3,16641 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Phoenix
- Douglas CunninghamPhoenix$1.8M
- Mitchell EdelsteinPhoenix$741K
- Heather ElwoodPhoenix$236K
- Ahmed AghaPhoenix$92K
- Valerie MirandaPhoenix$91K
- Randy GelowPhoenix$56K
- Gabrielle GoodrickPhoenix$32K
- Trisha TavaresPhoenix$32K
- Donald MulvaneyPhoenix$21K
- Carlos GarretonPhoenix$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.